176 related articles for article (PubMed ID: 28503657)
1. An amylin analog used as a challenge test for Alzheimer's disease.
Zhu H; Stern RA; Tao Q; Bourlas A; Essis MD; Chivukula M; Rosenzweig J; Steenkamp D; Xia W; Mercier GA; Tripodis Y; Farlow M; Kowall N; Qiu WQ
Alzheimers Dement (N Y); 2017 Jan; 3(1):33-43. PubMed ID: 28503657
[TBL] [Abstract][Full Text] [Related]
2. Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.
Tao Q; Zhu H; Chen X; Stern RA; Kowall N; Au R; Blusztajn JK; Qiu WQ;
J Alzheimers Dis; 2018; 62(2):597-609. PubMed ID: 29480193
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G
Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383
[TBL] [Abstract][Full Text] [Related]
4. Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.
Kimura R; MacTavish D; Yang J; Westaway D; Jhamandas JH
Mol Neurobiol; 2017 Jan; 54(1):748-754. PubMed ID: 26768593
[TBL] [Abstract][Full Text] [Related]
5. Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Qiu WQ; Zhu H
Front Aging Neurosci; 2014; 6():186. PubMed ID: 25120481
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.
Patrick S; Corrigan R; Grizzanti J; Mey M; Blair J; Pallas M; Camins A; Lee HG; Casadesus G
J Alzheimers Dis; 2019; 69(1):157-168. PubMed ID: 30958347
[TBL] [Abstract][Full Text] [Related]
7. Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease.
Zhu H; Xue X; Wang E; Wallack M; Na H; Hooker JM; Kowall N; Tao Q; Stein TD; Wolozin B; Qiu WQ
Neuropharmacology; 2017 Jun; 119():170-181. PubMed ID: 28363773
[TBL] [Abstract][Full Text] [Related]
8. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Lush CW; Chen K; Lacerte C; Burns C; McKay R; Weyer C; Horowitz M
Obesity (Silver Spring); 2007 May; 15(5):1179-86. PubMed ID: 17495194
[TBL] [Abstract][Full Text] [Related]
9. Amylin in Alzheimer's disease: Pathological peptide or potential treatment?
Mietlicki-Baase EG
Neuropharmacology; 2018 Jul; 136(Pt B):287-297. PubMed ID: 29233636
[TBL] [Abstract][Full Text] [Related]
10. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
11. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition.
Grizzanti J; Corrigan R; Casadesus G
J Alzheimers Dis; 2018; 66(1):11-23. PubMed ID: 30282360
[TBL] [Abstract][Full Text] [Related]
13. Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti J; Corrigan R; Servizi S; Casadesus G
J Neurol Neuromedicine; 2019; 4(1):12-16. PubMed ID: 31511851
[TBL] [Abstract][Full Text] [Related]
14. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
15. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.
Qiu WQ
Neuroscience; 2017 Jul; 356():44-51. PubMed ID: 28528968
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of gastric emptying.
Young A
Adv Pharmacol; 2005; 52():99-121. PubMed ID: 16492543
[TBL] [Abstract][Full Text] [Related]
17. Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin).
BioDrugs; 2003; 17(1):73-9. PubMed ID: 12534323
[TBL] [Abstract][Full Text] [Related]
18. Pramlintide: profile of an amylin analog.
Lebovitz HE
Expert Rev Endocrinol Metab; 2012 Nov; 7(6):599-609. PubMed ID: 30754127
[TBL] [Abstract][Full Text] [Related]
19. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.
Smith SR; Blundell JE; Burns C; Ellero C; Schroeder BE; Kesty NC; Chen KS; Halseth AE; Lush CW; Weyer C
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E620-7. PubMed ID: 17505051
[TBL] [Abstract][Full Text] [Related]
20. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
